LadRx Corporation
- Jurisdiction
United States - LEI
549300XDBGI8PTJRSA42 - ISIN
US2328286081 (CYTR )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. Read full profile
Stock price
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€2.63B - EBIT margin
0.0% - Net income
-€4.36B - Net margin
0.0%
Statement period: - (published )
Dividends
- Last dividend amount
-
$0.29 - Ex date
-